Browse the evidence

Online guided self-help interventions using Acceptance and Commitment Therapy (ACT) for weight maintenance following prior weight loss programs offer cost-effective value for the NHS, with optimal trial designs showing significant expected net benefits.

If you have completed a weight loss program, look for online guided self-help programs that use Acceptance and Commitment Therapy (ACT). These digital tools are designed to help you maintain your weight loss long-term and are increasingly recognized as cost-effective for healthcare systems.

Early intensive intervention targeting stringent glycaemic control (HbA1c ≤ 6.5%) and significant weight loss (≥10%) at diagnosis improves long-term prognosis and prevents microvascular complications in younger patients with longer life expectancy.

If you are diagnosed with Type 2 Diabetes and are under 65, do not accept a standard HbA1c target of 7% as the end goal. Work with your doctor to aim for a stricter target (≤ 6.5%) and significant weight loss (10% or more) immediately. This early, intensive approach is critical for preventing long-term complications like eye and kidney damage, especially given your longer life expectancy.

GLP-1 receptor agonists (GLP-1 RA) and SGLT2 inhibitors are preferred first-line treatments for patients with Type 2 Diabetes and obesity or cardiovascular disease, respectively, due to their weight-reducing and cardioprotective properties.

If you have Type 2 Diabetes and obesity or heart disease, ask your doctor about GLP-1 receptor agonists or SGLT2 inhibitors. These drugs not only help control blood sugar but also promote weight loss and protect your heart, making them preferred choices over metformin alone for many patients.

Higher educational attainment is associated with significantly higher weight management nutrition knowledge scores.

If you have less formal education, do not assume you cannot understand nutrition. Seek out dietitians who provide structured, personalized education. The study shows that ongoing counseling can help overcome educational barriers to understanding weight management.

Higher adherence to the PURE diet score is significantly associated with lower odds of depression and anxiety in adults at high cardiovascular risk, with the association being statistically significant in women but not in men.

Focus on adding fruits, vegetables, legumes, nuts, fish, and whole-fat dairy to your daily diet. This pattern, known as the PURE diet, is linked to lower risks of depression and anxiety, especially in women. You do not need to strictly eliminate animal products or dairy to see benefits; the key is overall dietary quality and nutrient density rather than extreme restriction.

A remotely delivered, 12-month GLP-1RA (semaglutide) supported weight management program achieves significant weight loss (mean 19.1% of starting weight) in participants who maintain an active subscription, but high withdrawal rates (60.4%) limit generalizability.

If you have obesity and are considering a GLP-1RA like semaglutide, a remote program can help you lose significant weight (around 19% on average) if you stick with it. However, be aware that many people drop out, often due to side effects or cost. To succeed, you need to be committed to the weekly injections and the digital support, and understand that stopping the medication likely leads to weight regain.

Virtual weight care programs prescribing a broad range of antiobesity medications alongside behavior change achieve clinically significant weight loss (mean 8.0% at 12 months) in real-world settings, with higher engagement correlating with greater weight loss.

Engage with a structured virtual weight care program that combines medication with behavioral support. Higher engagement with the program (logging weight weekly, interacting with coaches) correlates with greater weight loss (up to 12%). You do not need the most expensive medications to achieve significant results; a broad range of medications, when paired with consistent engagement, can lead to clinically meaningful weight loss.

Tirzepatide produces significantly greater long-term total body weight loss and fat mass reduction compared to Semaglutide in real-world clinical practice, with effects becoming distinct after 6 months.

If you are choosing between Semaglutide and Tirzepatide for long-term weight management, Tirzepatide offers significantly greater weight loss after 12 months. To maximize results and protect your muscle, you must combine the medication with a program that includes strength training twice a week and a protein intake of 60-90 grams daily.

Females experience significantly greater weight loss than males when treated with incretin-based obesity medications (Semaglutide and Tirzepatide).

If you are male, expect that your weight loss may be slower than that of female peers taking the same medication. This is a known biological response. Do not be discouraged; the medication still provides significant metabolic benefits and fat loss, even if the scale moves slower.

Myostatin acts as a negative regulator of muscle hypertrophy and cardiac pathological hypertrophy, and its inhibition or reduction through exercise can promote muscle growth and protect against certain cardiac dysfunctions.

Consistent exercise naturally lowers myostatin, a protein that limits muscle growth. This is one reason why regular resistance training is effective for building muscle.

GLP-1RAs and GIP/GLP-1RAs (liraglutide, semaglutide, tirzepatide) cause significant loss of fat-free (muscle) mass in older adults with sarcopenic obesity, posing a risk that may outweigh benefits if not managed.

If you are an older adult with sarcopenic obesity considering GLP-1 medications, expect to lose some muscle along with fat. To protect your strength, you must combine the medication with regular resistance exercise and eat enough protein (1.0-1.2g per kg of body weight). Work with your doctor to start slowly and monitor your function.

Bariatric surgery and incretin-based therapies (GLP-1 RAs, tirzepatide) reduce pancreatic disease burden and improve metabolic profiles relevant to pancreatic pathology.

If you are considering weight loss medications like GLP-1 agonists (e.g., semaglutide) or dual agonists (e.g., tirzepatide), current evidence suggests they do not increase the risk of pancreatitis or pancreatic cancer. They may actually help reduce pancreatic inflammation and disease burden by improving metabolic health.

MSG consumption may increase food intake and palatability, leading to higher energy intake and potential weight gain, particularly in animal models.

MSG makes food taste better, which can lead to eating more. If you notice you eat larger portions when MSG is present, consider moderating your intake of processed foods that contain it.

GLP-1 receptor agonists and dual GIP/GLP-1 agonists cause unintended nutritional complications, including severe caloric restriction (<800 kcal/day), lean body mass loss (approx. 25-45% of total weight loss), micronutrient deficiencies, dehydration, and rare ketoacidosis, necessitating structured dietitian-led monitoring.

If you are taking GLP-1 medications like semaglutide or tirzepatide, do not rely on appetite alone to guide your diet. You are at risk of losing muscle and missing essential nutrients. Aim for at least 1200-1500 kcal/day and 1-1.4 grams of protein per kilogram of body weight daily. Prioritize nutrient-dense foods and stay hydrated. Work with a dietitian to monitor your intake and adjust your plan to prevent fatigue, dizziness, or muscle loss.

GLP-1 receptor agonist (GLP-1RA) therapy is associated with clinically relevant risks of protein, vitamin, and mineral deficiencies due to reduced caloric and nutrient intake.

If you are taking a GLP-1 medication like semaglutide or tirzepatide, you are likely eating less, which means you might not be getting enough vitamins and minerals. You should prioritize nutrient-dense foods and discuss baseline blood testing for Vitamin D, B12, Iron, and Calcium with your doctor. Do not assume that because this is a medication and not surgery, you are exempt from nutritional monitoring.

GLP-1RA therapy frequently leads to inadequate protein intake, resulting in loss of lean body mass and potential sarcopenia.

To prevent muscle loss while on GLP-1 medication, you must consciously prioritize protein in your diet. Aim for 1.2-2.0 grams of protein per kilogram of body weight daily. If you are struggling to eat enough protein, consider high-protein food choices or supplements, and discuss this with your healthcare provider.

Zinc supplementation (50 mg oral zinc acetate, 2x/day for 14 weeks) improves insulin secretion specifically in individuals with the SLC30A8 rs13266634 CT/TT genotype, demonstrating a genotype-dependent response to micronutrient intervention.

If you are considering zinc supplementation for insulin resistance, check your SLC30A8 genotype first. If you carry the CT or TT variant of rs13266634, 50mg of zinc acetate twice daily for 14 weeks may significantly boost your fasting insulin levels. If you have the CC genotype, this specific intervention may not offer the same benefit.

High adherence to a Mediterranean diet improves inflammatory biomarkers (triglycerides, hsCRP) in individuals with the TNF rs1800629 GG genotype, demonstrating that dietary patterns can modulate genetic inflammation risk.

If you have the TNF rs1800629 GG genotype, you are genetically predisposed to higher inflammation and triglycerides. Adopting a Mediterranean diet for at least one year can significantly improve these markers, reducing your cardiovascular risk. This is a key example of how diet can counteract genetic inflammation.

Lifestyle interventions (diet and exercise) significantly improve sperm normal morphology and progressive motility in men with obesity, whereas bariatric surgery and pharmacotherapy (metformin/liraglutide) show no clinically significant improvements in semen parameters or DNA damage.

If you are overweight and trying to conceive, focus on sustainable lifestyle changes (diet and exercise) rather than seeking surgical or pharmacological weight loss solutions solely for fertility. Lifestyle changes have been shown to improve sperm morphology and motility, whereas surgery and weight-loss drugs have not shown consistent benefits for semen quality in this population.

Genetic variants in GLP1R (e.g., rs6923761), GIPR (e.g., rs2287019, rs10423928), and TCF7L2 (rs7903146) significantly influence individual response to tirzepatide, affecting glycemic control, weight loss, and side effect profiles.

Your genes can affect how well tirzepatide works for you. If you have certain genetic variants, you might need a different dose or might experience different side effects. Talk to your doctor about genetic testing to personalize your treatment.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce modest weight loss (2.3–5%) in breast cancer patients, which is significantly attenuated compared to non-cancer populations, likely due to concurrent endocrine therapy.

If you have breast cancer and are taking hormone-blocking therapy, GLP-1 drugs like semaglutide will likely help you lose some weight, but not as much as they do for people without cancer. Expect a modest loss (around 2-5%) rather than dramatic results. This is likely because your cancer treatment changes your metabolism. It appears safe regarding cancer recurrence, but discuss timing with your oncologist.

GLP-1 receptor agonist use in breast cancer patients does not increase the risk of cancer recurrence and may reduce cardiovascular morbidity.

For breast cancer patients, GLP-1 drugs appear safe regarding cancer recurrence. They may also offer significant cardiovascular protection, which is valuable since some cancer treatments can stress the heart. This benefit exists independently of weight loss.

Sympathomimetic agents (phentermine, phentermine/topiramate, naltrexone/bupropion) cause mild gastrointestinal side effects (constipation, dry mouth, nausea) with lower discontinuation rates compared to GLP-1 agonists.

If you take a sympathomimetic medication like phentermine or naltrexone/bupropion, you may experience mild side effects like constipation or dry mouth. These are generally less severe than the GI side effects associated with GLP-1 agonists. Stay hydrated and monitor your symptoms.

Weight loss, particularly through GLP-1 based pharmacotherapy (e.g., Tirzepatide), significantly reduces OSA severity and improves cardiometabolic markers like blood pressure, offering a promising alternative or adjunct to CPAP.

Losing weight is one of the most effective ways to treat OSA. New medications like Tirzepatide are showing great promise in reducing breathing pauses and improving blood pressure in obese patients. However, access and cost remain significant barriers.